Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial (PARTO-MAP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03675061|
Recruitment Status : Recruiting
First Posted : September 18, 2018
Last Update Posted : March 25, 2020
Prematurity is defined as birth before 37 weeks of amenorrhea. It is the leading cause of perinatal morbidity and mortality. It is estimated that premature births to 15 million worldwide in 2010, including 60,000 children in France (7,4% of births) and 12000, born before 32 weeks of amenorrhea (term defining great prematurity). More than half of these births follow spontaneous work.
Before 34 weeks of amenorrhea, prematurity requires specific maternal-fetal management centered primarily on antenatal corticosteroid treatment for fetal maturation including 2 intramuscular injections at 24 hour intervals. This cure can only be done once and its benefit is proven in the 7 (to 14) days before the birth (recommendation for the clinical practice of the French National College of Obstetricians and Gynecologists of December 2016). The single course of antenatal corticosteroids before 34 weeks of amenorrhea is associated in the neonatal period with reduction in morbidity and mortality, and in the long term with an improvement of the survival without sequelae, if the full cure is administered in the 7, to 14, days before birth. The second key element of the management of a premature delivery threats is the admission in a pediatric structure adapted to the degree of prematurity.
The care of a premature delivery threats before 34 weeks of amenorrhea care leads to hospitalization with possible transfer to a maternity of pediatric adapted level, tocolysis, a biological and bacteriological assessment, and, sometimes, other examinations and treatments.
The prediction of premature labor is a challenge. Current methods, such as vaginal examination, cervicometry and detection of fetal fibronectin, make it possible to obtain a negative predictive value (NPV) approaching 100% but a poor positive predictive value (PPV), thus 8 out of 10 patients hospitalized and treated for premature delivery threat no not give birth within 7 days, or even before 34 weeks of amenorrhea. A better prediction of preterm delivery has two benefits: administer antenatal corticosteroid therapy in high-risk patients at the right time and not treat not-at risk patients.
The PartoSure® test, which detects the placental protein vaginal alphamicroglobulin-1 (PAMG-1), has satisfactory metrological qualities according to observational studies : NPV 98% and PPV 75% of delivery within 7 days.
However this test has never been evaluated in real clinical condition. In our study, the result of the test becomes decisional for the care.
The hypothesis is that use of this test will improve the prediction of preterm delivery during a first consultation for preterm delivery threat and thus allow more frequent prenatal corticosteroid treatment in optimal period, avoiding treating non-at risk patients.
|Condition or disease||Intervention/treatment||Phase|
|Pregnancy Preterm||Other: Current care Device: PartoSure Test negative Device: PartoSure Test positive||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||128 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Vaginal PAMG-1 Detection by PartoSure Test in Preterm Delivery Threat in Actual Clinical Situation: Randomized Controlled Trial|
|Actual Study Start Date :||December 11, 2018|
|Estimated Primary Completion Date :||June 11, 2021|
|Estimated Study Completion Date :||June 11, 2021|
Current care : The management of the preterm delivery risk without biochemical test, with hospitalization of the patient, initiation of tocolysis and a complete corticosteroid treatment.
Other: Current care
Tocolysis and a complete corticosteroid treatment.
Each women have a biochemical test = PartoSure Test.
Device: PartoSure Test negative
Biochemical test and nifedipine tocolysis, then return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea .
Device: PartoSure Test positive
Biochemical test and tocolysis and a complete corticosteroid treatment. then if situation is stable, return at home with the midwife's visit at home twice a week up to 34 weeks of amenorrhea
- Comparison of the two strategies used for patients with preterm delivery threat and intact membranes [ Time Frame: 7 days ]Compare impact of experimental diagnosis strategy (binding usual diagnosis strategy and research of vaginal PAMG-1 with PartoSure® test) with usual diagnosis strategy only, in population of patients with preterm delivery threat and intact membranes, about frequency of appropriate care concerning corticosteroids cure.
- Comparison of frequency of prescription of antenatal corticosteroids by following the prescription of patients [ Time Frame: 14 days ]Compare frequency of prescription adequacy of antenatal corticosteroids cure appropriate in the 14 days of inclusion between the both diagnosis strategies
- diagnosis performances [ Time Frame: 7 days ]Assess diagnosis performances (NPV, PPV, Se, Sp) of PartoSure® test in actual clinical situation
- Change of care following initial care [ Time Frame: 14 days ]Assess care modifications consecutive of initial care by following the numbers of hospitalisation for preterm delivery prediction
- Health strategy [ Time Frame: 14 days ]Compare the differences of health expenditure cost under experimental strategy and usual strategy
- Neonatal morbidity [ Time Frame: An average of 40 weeks ]Compare neonatal morbidity between both group
- Neonatal mortality [ Time Frame: An average of 40 weeks ]Compare neonatal mortality between both group
- Level of preterm delivery prediction [ Time Frame: 7 days ]Assess in the experimental group the level of preterm delivery prediction in the 7 days
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03675061
|Contact: Jacob HANNIGSBERG, PH||220.127.116.11.32 ext +email@example.com|
|Contact: Sarah HERMANN||18.104.22.168.32 ext +33|
|Brest, France, 29609|
|Contact: Jacob HANNIGSBERG firstname.lastname@example.org|